REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
News

Therapy-Resistant Basal Cell Carcinoma Patients React Positively to New Treatment

Carcinoma
Immunotherapy found to be effective for the treatment of basal cell carcinoma skin cancer

Basal cell carcinoma (BCC) is a type of cancer that most often develops on areas of skin exposed to the sun, such as the face, and is the most common form of skin cancer. Traditionally, BCC is treated with surgery to remove the malignant tissue. When the type of the tumor does not allow for surgery, doctors often employ biological drugs. However, the latter can cause severe side effects.

Highly effective, and with fewer side effects compared to other BCC immunotherapy drugs, Cemiplimab offers new hope for patients. A PD-1 inhibitor, Cemiplimab blocks the activity of certain checkpoint proteins that tend to be present on the surface of cells and signal immune cells not to attack.

According to a recent study by Sheba Medical Center, Cemiplimab is highly effective in treating BCC, as the tumor shrunk significantly in 30 percent of participants, while 60 percent experienced some reduction in size or a halt in development. These patients either did not react to standard biological treatments or experienced severe side effects.

Related
virtual care
Nuvo Group and Sheba Develop AI-Powered Gestational Diabetes Management Platform
A groundbreaking gestational diabetes pilot was recently completed by the two organizations, deploying Nuvo's INVU platform at Sheba’s Beyond Virtual Hospital, simplifying care for pregnant…
Read More
pain treatment for pancreatic cancer
Breakthrough Study: Radiation Therapy Effective for Pain Management in Cancer Patients
Pancreatic cancer, the 12th most common cancer worldwide, is associated with pain in approximately 75% of patients at the time of diagnosis, and as much…
Read More
arc center
News Nov 30.
Real-Time Detection of Cancerous Biomarkers With Artificial Intelligence
Lung cancer is the most common cancer and accounts for 1.76 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all…
Read More